JDRF Partner ViaCyte to Immediately Initiate Type 1 Diabetes Clinical Trial

JDRF’s partner ViaCyte recently announced the U.S. Food and Drug Administration (FDA) is allowing them to move forward with a clinical trial of its innovative type 1 diabetes (T1D) encapsulated cell replacement therapy called VC-01™ product candidate. The company plans to immediately initiate the first ever clinical evaluation of a stem cell-derived islet replacement therapy […]

Oxygen – A Key Ingredient of Life

JDRF partners with Beta-O2 Technologies to develop a novel implantable encapsulation device for type 1 diabetes The dream for everyone with type 1 diabetes (T1D) is to permanently restore their body’s lost ability to produce insulin. This defines a cure for T1D and remains a top priority for JDRF. As we work towards this longer-term […]

Rebalancing the Immune System

Novel therapy to increase beneficial immune cells shows promise in pilot type 1 diabetes clinical study Type 1 diabetes (T1D) is caused when a person’s immune system mistakenly destroys their insulin-producing beta cells. How and why this misguided attack begins remains a mystery, but JDRF research has helped shed light on the disease process, opening […]

Potential Breakthrough in Encapsulation Technology

JDRF-funded researchers develop novel method of protecting islets for implantation into people with type 1 diabetes Pancreatic islet transplantation has restored insulin independence in some individuals with type 1 diabetes (T1D), but the procedure is not widely available due to the limited supply of donated islets and the need for strong immunosuppressive drugs to prevent […]

Top 10 Advances in T1D Research

JDRF-supported progress in fiscal year 2014 JDRF sets ambitious goals for progress in type 1 diabetes (T1D) research each year because our supporters inspire us to aim higher. We invite you to read about the real impact our strategic plan is making and hope you are as inspired as we are as each of these […]

Redefining the Diagnosis of Type 1 Diabetes

Updated criteria could open new possibilities for intervention before symptoms appear JDRF is leading a pertinent discussion in the diabetes field about what defines a diagnosis of type 1 diabetes (T1D). At the 14th Annual Rachmiel Levine Diabetes and Obesity Symposium today, Richard Insel, M.D., JDRF’s chief scientific officer, reviewed evidence supporting the need to […]

Redefining the Diagnosis of Type 1 Diabetes

JDRF is leading a pertinent discussion in the diabetes field about what defines a diagnosis of type 1 diabetes (T1D). At the 14th Annual Rachmiel Levine Diabetes and Obesity Symposium today, Richard Insel, M.D., JDRF’s chief scientific officer, reviewed evidence supporting the need to change the diagnostic criteria of T1D to recognize the fact that […]

JDRF-Led Workshop Explores Progress toward an Artificial Pancreas System

Leading experts from industry, academia, and government came together the second week of April in Bethesda, MD, to discuss innovation in the development of an artificial pancreas system at a workshop hosted by the National Institutes of Health, the Food and Drug Administration (FDA), and JDRF. A commercially-viable artificial pancreas system would mimic the biological […]